correlation was found with time to repedus~on (r=O.llO; ~~0.20). A significant correlation in UA patients significantly increased neutrophil apoptotic rate (36%; 21.47%. p=O.O06 vs was also observed between AEDV and peak creatine-kinase (p=O.O04; r=-0.649). baseline); moreover apoptotic rate following abciximab was not different from that
Background: One of the challenges for gene therapies IS to be able to switch on or off gene expression, ideally by a pathophysiological stimulus. For the purpose of treating myocardial ischemia, we have used hypoxia as the stimulus. Hypoxia-inducible factor 1 a (HIF-la ) is the master regulator for hypoxia rasponsas. Its protein stability is regulated by its oxygen-dependent degradation (ODD) domaln, which triggers a proteosome-mediated degradation only under normoxia. Therefore, we invented an oxygen-sensitive regulator (OSR) as hypoxic gene switch by fusing the ODD domain in between the DNA binding domain of yeast GAL4 and the activation domain of ~65.
Method:
The OSR recognizes and activates a minimal promoter containing GAL4 upstream activating sequences. Three reporter genes. luciferase. p -galactosldase and secreted alkaline phosphatase were inserted downstream of this minimal promoter, respectively. The myosin light chain-2v (MLC-2~) promoter was used to restrict the expression of OSR in the heart. The plasmids were co-transfected into embryonic and adult rat cardiomyocyies and tested under hypoxia (1% Q or 0.5% 02) and normoxia (20% 0,).
Results: After transfection, the expression of tuciferase was induced under hypoxia 3 to 6 fold in embryonic cardiomyocytes and 16 fold in adult cardiomyocytes. When three dlfferent reporter plasmids were co-transfected with OSR. all of them were up-regulated 16 to 18 fold by hypoxia. The OSR could rapidly turn on gene expression with the hypoxic stimulus and turn it off after normal air was restored. Furthermore, the OSR dramatically amplified the power of the MLC-2~ promoter up to 300-fold but still maintained its cardiac specificity.
Conclusion:
The OSR invented in current study is a novel oxygen sensor and gene amplifier. more effective than either HIF-1 or hypoxia response element in switching on and amplifying a cardiac specific promoter. It can be adapted into an adeno-associated virus mediated '"vigilant vector" to deliver multiple protective genes to the heart, such as heme oxygenase-1, superoxide dismutase. and VEGF, and simultaneously turn them on in response to ischemla and off in normoxia.
BACKGROUND:
Cardiac troponln-I (cTnl) IS a more specific and sensitive biomarker than creatine kinase MB (CK-MB) for detection of myocardial damage. However, the impact of cTnl versus CK-MB on the rates of diagnosis of acute myccardial infarction (AMI) is unclear.
METHODS
Seven hundred seventy-six consecutive hospital admissions for suspected acute coronarv syndrome (ACS) to an urban acute care hospital over a four month period were analyzed
Patients were aged 16 to 84, residents of the seven-county Twin Cities metropolitan area. and had at least two separate sets of plasma biomarkers sent to the laboratory for evaluation of possible AMI during each hospital admission. cTnl and CK-MB assays (Dade Dimension) were performed concurrently.
RESULTS:
Using the 10% coefficient of variation (CV) cut-off adopted by the hospital (cTnl > 0.3 ng/mL and CK-MB > 5.0 ng/mL), 116 (14.9%) of the 776 consecutive ACS admlssions had positive cTnl. Of these, only 58 (50%) had positive CK-MB. Using a 99th percentile cut-off (cTnl > 0.1 ng/mL and CK-MB > 4.0 ng/mL) instead of the 10% CV cutoff would increase the number of CT&positive, CK-MB-negative admissions by 123%.
Using the receiver operator charactenstic curve-derived cut-off (cTnl > 0.6 ng/mL and CK-MB > 7.0 ng/mL) Instead of the 10% CV cut-off would decrease the number of cTnlpositive, CK-MB-negative admissions by 27%.
CONCLUSION:
Rates of diagnosis of AMI as determined by plasma biomarkers are substantially increased by criteria utilizmg cTnl compared to those utilizing CK-MB. Utilizing lower reference cut-offs for these plasma biomarkers markedly increases the rates of cTnl-positive, CK-MB-negative cases.
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Reconstituted 
Can Preinfarction Angina Limit Infarct Size in Patients With a First Q-Wave Myocardial Infarction Undergoing Primary Percutaneous Coronary Angioplasty?
1096-l 11 line (ACH) as an endothellum-dependent vasodilator, nitroglycerine (NG) as direct dilator of vascular smooth muscle cells, results beeing expressed as ml flow per 100 ml tissue;
and (2) positron emission tomography (PET) to assess myocardial perfusion at rest and during stress with adenosine, results beeing expressed as ratio of flow under stress/at rest. Experiments were performed before and after infusion of 80 mg rHDL per kg body weight and took place wlthin 7 days after diagnosis of ACS. All patients underwent percutaneous coronary intervention prior to randomization and were an current standard medical treatment.
Results 16 patients were included. ACH induced flow increased significantly after Infusion of rHDL (6.5 mllmin *2 to 8.0 mlimin ~2.4. p=O.O45). NG-induced blood flow too increased under rHDL as did PET assessed coronary flow reserve (11 mllmin e2.6 to 14.5 mllmin +2.7. p=O.O3 and 1.2 +O.l versus 2.0 kO.3, p=O.O18). Hemodynamlc parameters like mean arterial pressure and heart rate remained unchanged (73 mmHg versus 72 mmHg and 64 bpm versus 64 bpm). rHDL infuston was well tolerated in all patients.
Conclusions
rHDL on top of standard treatment increased vascular reagibility I" patients diagnosed with ACS. rHDL possesses pkitropic effects, its anti-inflammatory component may be the most potent as acute inflammation -measured for example as c-reactive protein IS a diagnostic key factor in the outcome of ACS. Despite endothelial function being an excellent surrogate, prospective clinical trials are needed in order to unravel the true potential of rHDL as novel treatment option. Background. Activated neutrophils have been found !n the coronary circulation of unstable angina (UA) patients. Neutrophil apoptosis. a key mechanism to control the intensity of the acute inflammatory response, is markedly reduced in unstable angina (UA)
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Abciximab Modulates Apoptosis of Circulating Neutrophils in Patients With Unstable Angina
BACKGROUND:
In patients with acute myocardial infarction (AMI), preinfarction angina (PA) promotes protective effects in the ischaemic myocardium, reducing the necrosis extension, but its impact in patients treated with primary percutaneous coronary angioplasty with stem deployment (PTST) is not already defined.
METHODS:
We studied 163 patients (mean age 66.4 years, 26.6% female), hospitalised in our coronary care unit for a first Q wave AMI and treated with successful primary PTST on the culprit lesion (TIM13 flow restored). 2D-echocardiographic left ventricular ejectlon function (LVEF), assessed in the first 24 hours after PTST, was successively compared with LVEF at hospital discharge (after 7-10 days). Myocardial reperfusion was considered successful when at least three of the following criteria were reached (MR.score): (I) early ST-resolution >50% or (2) early T-wave inversion in the frst 90 men after PTST.
(3) reperfusion ventricular arrhythmias, (4) CK and CK-MB time-to-peak <I2 hours. Major Adverse Cardiac Events (MACES) were evaluated at hospital discharge.
RESULTS:
In the study population patients with PA were 75 (mean age 70. Apoptosls was evaluated by flow heart failure (CHF) ,n viva, we measured arterial morphology in the resistance hindltmb cytometry (Annexln V-FITC, Immunotech, Marseille) after PMN isolation from peripheral vasculature in the rat coronary altery ligation model of CHF 5 days after adenoviral-mediblood samples (gradient centrifugation, Polymorphprep, Nicomed). Results (median; ated gene transfer of endothelial nitric oxide synthase (eNOS). The presence of CHF range). PMN apoptotic rate was signlfvxntly lower in UA (18%; 11.34%). than in SA was documented with increases (PcO.05) in left ventricular (LV) end-dk&olic pressure, (45%; 6-81% p=O 02) and healthy subjects (50%; 25.62%, p<O.OOl). Bolus of Abciximab decreases LV systolic pressure. and LV dP/dt. In the resistance vessels, of CHF rats,
